DOCSLIB.ORG

2318.Full-Text.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2318.Full-Text.Pdf Epidemiology/Health Services/Psychosocial Research ORIGINAL ARTICLE Impaired Fasting Glucose and Impaired Glucose Tolerance in Women With Prior Gestational Diabetes Are Associated With a Different Cardiovascular Profile 1 1 LUIS FELIPE PALLARDO, MD TERESA GARCIA-INGELMO, MD of abnormalities is associated with insulin 1 2 LUCRECIA HERRANZ, MD CRISTINA GRANDE, SCD resistance even in situations of normal 1 3 PILAR MARTIN-VAQUERO, BM MERCEDES JANEZ˜ , BM glucose tolerance (8,9). On the other hand, the establishment of two intermediate categories between normal glucose homeostasis and diabetes (impaired glucose tolerance [IGT] and OBJECTIVE — The purpose of this study was to investigate the association of cardiovascular impaired fasting glucose [IFG]) (10) has risk factors to impaired glucose tolerance (IGT) and to impaired fasting glucose (IFG) in women raised concern in which of these distur- with prior gestational diabetes mellitus (GDM). bances has a major role in predicting the RESEARCH DESIGN AND METHODS — We studied 838 women with prior GDM. development of type 2 diabetes or cardio- Postpartum glucose tolerance status was classified as normal, IFG, IGT, IFG plus IGT, and vascular disease. diabetes according to the World Health Organization criteria. Postpartum BMI, waist circum- The aim of this study was to investi- ference, blood pressure, triglyceride, cholesterol, and HDL cholesterol were assessed. gate the association of cardiovascular risk factors to IGT and IFG in the postpartum RESULTS — BMI and blood pressure were significantly higher in women with IFG than in evaluation of women with GDM. women with normal glucose status. BMI and waist circumference were significantly higher in women with IFG plus IGT than in women with normal glucose status. No differences were observed between women with IGT and normal glucose status. The prevalence of hypertension RESEARCH DESIGN AND and obesity was significantly increased in IFG compared with normal glucose status. The prev- METHODS — This research was con- alence of obesity and abnormal lipids was significantly increased in IFG plus IGT compared with ducted in the Diabetes and Pregnancy normal glucose status. IGT showed no increased prevalence of cardiovascular risk factors. Unit at the University Hospital La Paz in Madrid between 1992 and 2000. We CONCLUSIONS — Traditional cardiovascular risk factors have a stronger association with isolated IFG than with isolated IGT in women with prior GDM. studied 838 Caucasian women (mean age 32.4 Ϯ 4.6 years; mean parity 1.8 Ϯ 0.9) Diabetes Care 26:2318–2322, 2003 with singleton gestations complicated by GDM and who attended the initial post- partum assessment (3–6 months after de- livery) when lactation was concluded. omen with gestational diabetes creased LDL cholesterol and triglyceride The total number of women with single- mellitus (GDM) are at an in- levels and decreased HDL cholesterol lev- ton gestations who had a diagnosis of creased risk for the development els (2–4). Furthermore, changes in endo- W GDM during this period was 1,350. of diabetes (usually type 2) after preg- thelial function (5) and increased levels of Women who did not participate in the nancy (1). Likewise, women with prior adhesion molecules (6), together with a postpartum examination (37.9%) were GDM, when compared with women with higher prevalence of microalbuminuria similar to those who attended with regard no history of GDM, are found to have (7), abnormal electrocardiograms, and to age, parity, prepregnancy BMI, and de- higher BMI (2), higher blood pressure cardiovascular events (3) are observed in gree of glucose intolerance during preg- (3,4), and an altered lipid profile with in- women with prior GDM. This spectrum nancy. Ethical permission for the study ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● was received from the hospital ethical From the 1Department of Endocrinology, Division of Diabetes, Hospital Universitario La Paz, Madrid, Spain; committee, and informed consent was 2the Department of Biochemistry, Hospital Universitario La Paz, Madrid, Spain; and 3the Department of obtained from all subjects. Obstetrics and Gynecology, Hospital Universitario La Paz, Madrid, Spain. The diagnosis of GDM was made us- Address correspondence and reprint requests to Dr. L.F. Pallardo, Jefe de Servicio de Endocrinologı´a y ing the criteria of the National Diabetes Nutricio´n, Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. E-mail: [email protected]. Data Group (11) after performing a fast- Received for publication 29 October 2002 and accepted in revised form 16 April 2003. ing 3-h, 100-g oral glucose tolerance test Abbreviations: dBP, diastolic blood pressure; GDM, gestational diabetes mellitus; IFG, impaired fasting (OGTT) in all pregnant women with a glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; sBP, systolic blood pressure; screening test (50-g oral glucose chal- WHR, waist-to-hip ratio. Ն A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion lenge) showing a 1-h glucose value 140 factors for many substances. mg/dl (7.8 mmol/l). The screening test © 2003 by the American Diabetes Association. was performed at the first prenatal visit if 2318 DIABETES CARE, VOLUME 26, NUMBER 8, AUGUST 2003 Pallardo and Associates Table 1—Potential cardiovascular risk factors by postpartum glucose tolerance status Parameter Normal IFG IGT IFG plus IGT Diabetes P n 681 40 62 25 30 BMI (kg/m2) 25.3 Ϯ 4.1*†‡ 27.9 Ϯ 6.0* 25.4 Ϯ 4.5§ 29.0 Ϯ 5.4†§ 29.3 Ϯ 7.5‡ Ͻ0.001 Waist circumference (cm) 79.7 Ϯ 9.5†‡ 83.8 Ϯ 12.9 79.9 Ϯ 9.5§࿣ 88.8 Ϯ 12.1†§ 88.8 Ϯ 16.1‡࿣ Ͻ0.001 Triglyceride (mmol/l) 1.00 Ϯ 0.57‡ 1.08 Ϯ 0.62 1.20 Ϯ 0.69 1.37 Ϯ 0.86 1.39 Ϯ 1.15‡ Ͻ0.001 Cholesterol (mmol/l) 4.96 Ϯ 1.00 4.93 Ϯ 0.98 5.06 Ϯ 0.99 5.04 Ϯ 0.65 4.68 Ϯ 1.13 0.560 HDL cholesterol (mmol/l) 1.44 Ϯ 0.32 1.39 Ϯ 0.32 1.42 Ϯ 0.31 1.21 Ϯ 0.25 1.35 Ϯ 0.39 0.064 sBP (mmHg) 112.0 Ϯ 14.7* 118.4 Ϯ 16.8* 113.9 Ϯ 14.7 112.9 Ϯ 16.9 118.7 Ϯ 15.5 0.017 dBP (mmHg) 69.5 Ϯ 10.5*‡ 74.3 Ϯ 11.1* 71.3 Ϯ 11.2 68.9 Ϯ 12.5 75.5 Ϯ 11.0‡ 0.002 Data are means Ϯ SD. Significance of differences among pairs of group means (P Ͻ 0.05): *Normal versus IFG; †normal versus IFG plus IGT; ‡normal versus diabetes; §IGT versus IFG plus IGT; ࿣IGT versus diabetes. clinical characteristics were consistent els. Systolic (sBP) and diastolic (dBP) one-way ANOVA was used (F test) and with a high risk of GDM (obesity, family blood pressures were recorded with the post hoc tests were performed using the history of diabetes, personal history of patient in a sitting position after at least 5 Bonferroni method. Categorical variables GDM, or poor obstetric outcome) or at min of rest, using a sphyngomanometer. were compared using ␹2 and Fisher’s ex- 24–28 weeks of gestation when these The average of two blood pressure mea- act tests of significance. Multiple-variable characteristics were not present. surements was used for the analysis. An- logistic regression models were used to All women with a diagnosis of GDM thropometric measurements included estimate adjusted ORs. Association be- received nutrition counseling with indi- weight, height, and waist and hip circum- tween variables was evaluated using lin- vidualized caloric intake and providing ferences (13). BMI (kg/m2) was computed ear correlation coefficients and stepwise 50% of calories from carbohydrates, 30% from current weight and height, and multiple linear regression analysis. A P from fat, and 20% from protein. Self- waist-to-hip ratio (WHR) was computed value Ͻ0.05 was considered significant. glucose monitoring was performed by the from waist and hip circumferences. patients on alternate days. Insulin ther- Postpartum area under the glucose apy, given on the basis of a fasting blood curve was calculated by the trapezoidal RESULTS — At postpartum assess- glucose Ն105 mg/dl (5.8 mmol/l) or a 2-h method. A woman was classified as hav- ment of the 838 women with GDM, 681 postprandial blood glucose Ն120 mg/dl ing abnormal lipids if she had any of the women (81.3%) had a normal glycemic (6.7 mmol/l) on two or more occasions, following characteristics: triglyceride lev- status, 30 (3.5%) had diabetes, 40 (4.8%) was needed in 386 women (46.1%). els Ն150 mg/dl (1.69 mmol/l), HDL cho- had IFG, 62 (7.4%) had IGT, and 25 (3%) At postpartum assessment, a standard lesterol levels Յ39 mg/dl (1.01 mmol/l), had IFG plus IGT. Mean age was 32.5 Ϯ 75-g OGTT was given to 834 women (4 or total cholesterol levels Ն200 mg/dl 4.2 years for women with normal glyce- women had fasting glucose values that (5.17 mmol/l). Obesity was defined as the mic status, 32.6 Ϯ 4.8 years for women were diagnostic of diabetes). Reclassifica- presence of BMI Ն30 kg/m2 and/or WHR with diabetes, 32.8 Ϯ 5.1 years for tion of glycemic status was done accord- Ն0.85. Hypertension was defined as the women with IFG, 32.7 Ϯ 4.7 years for ing to the criteria of the World Health presence of sBP Ն140 mmHg and/or dBP women with IGT, and 32.8 Ϯ 4.8 years Organization (12) with the following Ն90 mmHg.
Load more

Recommended publications
  • Diabetes - High Blood Sugar After Hours Telephone Triage Protocols | Adult | 2019
    Diabetes - High Blood Sugar After Hours Telephone Triage Protocols | Adult | 2019 DEFINITION ⦁ Patient with known diabetes mellitus ⦁ Has a high blood sugar (hyperglycemia), defined as a blood glucose > 200 mg/dL (11 mmol/L) ⦁ Has symptoms of high blood sugar ⦁ Has questions regarding high blood sugar SYMPTOMS of High Blood Sugar (Hyperglycemia) include: ⦁ Mild hyperglycemia: Most often patient will have no symptoms. ⦁ Moderate hyperglycemia: polyuria, polydipsia, fatigue, blurred vision. ⦁ Severe hyperglycemia: confusion and coma. ⦁ Diabetic ketoacidosis (DKA): fruity odor on breath, vomiting, rapid breathing, weakness, confusion, and coma. INITIAL ASSESSMENT QUESTIONS 1. BLOOD GLUCOSE: "What is your blood glucose level?" 2. ONSET: "When did you check the blood glucose?" 3. USUAL RANGE: "What is your glucose level usually?" (e.g., usual fasting morning value, usual evening value) 4. KETONES: "Do you check for ketones (urine or blood test strips)?" If yes, ask: "What does the test show now?" 5. TYPE 1 or 2: "Do you know what type of diabetes you have?" (e.g., Type 1, Type 2, Gestational; doesn't know) 6. INSULIN: "Do you take insulin?" "What type of insulin(s) do you use? What is the mode of delivery? (syringe, pen (e.g., injection or pump) 7. DIABETES PILLS: "Do you take any pills for your diabetes?" If yes, ask: "Have you missed taking any pills recently?" 8. OTHER SYMPTOMS: "Do you have any symptoms?" (e.g., fever, frequent urination, difficulty breathing, dizziness, weakness, vomiting) 9. PREGNANCY: "Is there any chance you are pregnant?"
    [Show full text]
  • Assessing Blood Glucose Regulation
    Functional Medicine University’s Functional Diagnostic Medicine Training Program Mod 4 * FDMT533B Primary and Advanced Testing: Assessing Blood Glucose Regulation By Wayne L. Sodano, D.C., D.A.B.C.I., & Ron Grisanti, D.C., D.A.B.C.O., M.S. http://www.FunctionalMedicineUniversity.com Limits of Liability & Disclaimer of Warranty We have designed this book to provide information in regard to the subject matter covered. It is made available with the understanding that the authors are not liable for the misconceptions or misuse of information provided. The purpose of this book is to educate. It is not meant to be a comprehensive source for the topic covered, and is not intended as a substitute for medical diagnosis or treatment, or intended as a substitute for medical counseling. Information contained in this book should not be construed as a claim or representation that any treatment, process or interpretation mentioned constitutes a cure, palliative, or ameliorative. The information covered is intended to supplement the practitioner’s knowledge of their patient. It should be considered as adjunctive and support to other diagnostic medical procedures. This material contains elements protected under International and Federal Copyright laws and treaties. Any unauthorized reprint or use of this material is prohibited. Functional Medicine University; Functional Diagnostic Medicine Training Program/Insider’s Guide Module 4: FDMT 533B: Primary and Advanced Testing: Assessing Blood Glucose Regulation Copyright © 2010 Functional Medicine University, All Rights Reserved Functional Medicine University’s Functional Diagnostic Medicine Training Program Module 4: FDMT 533B: Primary and Advanced Testing: Assessing Blood Glucose Regulation By Wayne L.
    [Show full text]
  • Hyperglycemia – Prediabetes
    North Dakota Family Planning Program Clinical Protocol Manual Health Maintenance – HM 8 Hyperglycemia – Prediabetes DEFINITION Hyperglycemia is an excess of glucose in the blood. Prediabetes is a condition when blood glucose levels are higher than normal but not yet high enough to be diagnosed as diabetes. (Prediabetes is also known as Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) depending on which test was used to detect it. IGT uses the oral glucose tolerance test and IFG uses the fasting plasma glucose test.) SUBJECTIVE May include: 1. No symptoms 2. Family history of diabetes 3. Weight changes 4. Fatigue, blurred vision, recurrent vulvovaginal candidiasis 5. History of gestational diabetes or birth weight of newborn 9 lbs. or greater 6. Polydipsia, polyphagia, or polyuria 7. 20% over ideal body weight; sedentary lifestyle 8. Decreased wound healing 9. Race (higher incidence of diabetes among American Indian, Hispanic, and African American population) 10. History of hypertension 11. History of decreased HDL and increased triglycerides 12. History of Polycystic Ovarian Syndrome or Metabolic Syndrome 13. History of antipsychotic medication therapy OBJECTIVE May include: 1. Blood pressure 2. Height and weight 3. Complete physical exam. Acanthosis Nigricans may be noted in axillae, groin, and/or neck LABORATORY May refer for: 1. Hyperglycemia a. lab of choice may include one or more of the following: i. Fasting plasma glucose (FPG) a) Prediabetes: FPG between 100 mg/dl to 125 mg/dl b) Diabetes: FPG is > 126 mg/dl ii. Oral Glucose Tolerance Test (OGTT) a) Prediabetes: OGTT 140mg/dl to 199 mg/dl b) Diabetes: OGTT 200mg/dl or higher iii.
    [Show full text]
  • Most Women with Previous Gestational Diabetes Mellitus Have Impaired Glucose Metabolism After a Decade
    International Journal of Molecular Sciences Article Most Women with Previous Gestational Diabetes Mellitus Have Impaired Glucose Metabolism after a Decade Wahlberg Jeanette 1,2, Ekman Bertil 1,* and Arnqvist J. Hans 2 1 Department of Endocrinology and Department of Medical and Health Sciences, Linköping University, S-581 85 Linköping, Sweden; [email protected] 2 Department of Endocrinology and Department of Clinical and Experimental Medicine, Linköping University, S-581 85 Linköping, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-(0)101-030-000; Fax: +46-(0)101-033-502 Received: 22 October 2018; Accepted: 20 November 2018; Published: 23 November 2018 Abstract: Of 1324 women diagnosed with gestational diabetes mellitus (GDM) in Sweden, 25% reported >10 years after the delivery that they had developed diabetes mellitus. We assessed the long-term risk of all glucose metabolic abnormalities in a subgroup of these women. Women (n = 51) previously diagnosed with GDM by capillary blood glucose ≥9.0 mmol/L (≈plasma glucose ≥10.0 mmol/L) after a 2 h 75 g oral glucose tolerance test (OGTT) were included. All underwent a clinical and biochemical evaluation, including a second 2 h 75 g OGTT. Individuals with known type 1 diabetes were excluded. At the follow-up, 12/51 (24%) reported previously diagnosed type 2 diabetes. Another four cases were diagnosed after the second OGTT, increasing the prevalence to 16/51 cases (31%). Impaired fasting plasma glucose (IFG) was diagnosed in 13/51 women and impaired glucose tolerance (IGT) in 10/51 women, leaving only 12 women (24%) with normal glucose tolerance.
    [Show full text]
  • CDHO Factsheet Diabetes Mellitus
    Disease/Medical Condition DIABETES MELLITUS Date of Publication: May 19, 2015 (also known as “diabetes” or “DM”) Is the initiation of non-invasive dental hygiene procedures* contra-indicated? No Is medical consult advised? ........................................ No, unless previously diagnosed diabetes is thought to be poorly controlled and/or there are significant untreated complications (e.g., infection or renal/cardiovascular disease). Urgent referral (i.e., to the emergency room) should occur if diabetic ketoacidosis1 or significant hypoglycemia is suspected. If diabetes is newly suspected based on the patient/client’s presenting signs/symptoms or history (including history of fasting 2 blood glucose ≥ 7.0 mmol/L [126 mg/dL], 2-hour postprandial blood glucose ≥11.1 mmol/L [200 mg/dL], or hemoglobin A1C ≥ 6.5%), the patient/client should be referred to a physician/nurse practitioner for definitive diagnosis and medical management. Is the initiation of invasive dental hygiene procedures contra-indicated?** Possibly, under certain circumstances of poor diabetes control. See below under “medical clearance”. Is medical consult advised? ........................................ See above. Consultation may also be required for consideration of antibiotic prophylaxis (see below) and for clearance after postponement of treatment. Is medical clearance required? ................................... No, assuming diabetes is well controlled. — Yes, if blood glucose is < 3.9 mmol/L [70 mg/dL] or is > 11.1 mmol/L [200 mg/dL]). Such clearance is particularly important in the presence of various comorbidities3. Blood glucose < 3.9 mmol/L [70 mg/dL] should typically involve prompt administration of carbohydrates. — Yes, if there are any concerns about the patient/client’s suitability for invasive procedures regardless of blood glucose level (including oral infection or infection elsewhere in the body).
    [Show full text]
  • Clinical Practice Guidelines for Diabetes Management
    Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can lead to complications such as heart disease, stroke, kidney disease, blindness, nerve damage, gum infections, and peripheral vascular disease. Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), and an A1C of 5.7-6.4% are included in a category of increased risk for future diabetes (also known as pre-diabetes). This is defined as blood glucose or A1C levels higher than normal but not high enough to be characterized as diabetes. People with IFG, IGT, and an increase A1C are at risk for developing type 2 diabetes and have an increased risk of heart disease and stroke. With modest weight loss and moderate physical activity, people with pre-diabetes can delay or prevent type 2 diabetes. A1C testing is an appropriate test for diagnosing diabetes when A1C is greater than or equal to 6.5%. Diagnosis should be confirmed by a repeat A1C test unless clinical symptoms and glucose levels over 200 mg/dL are present. A1C testing may not be reliable due to patient factors which preclude its interpretation (e.g. any anemia, hemoglobinopathy or abnormal erythrocyte turnover). In this case, previously recommended diagnostic measures should be used (fasting plasma glucose and 2 hour oral glucose tolerance test). American Diabetes Association Criteria for testing for IFG and Diabetes in asymptomatic adults 1. All adults with a BMI > 25 and have additional risk factors Physical inactivity First-degree relative with diabetes High risk ethnic population: African American, Latino, Native American, Pacific Islander.
    [Show full text]
  • Impaired Fasting Glucose and Impaired Glucose Tolerance Implications for Care
    Reviews/Commentaries/ADA Statements CONSENSUS STATEMENT Impaired Fasting Glucose and Impaired Glucose Tolerance Implications for care 1 5 DAVID M. NATHAN, MD ROBERT R. HENRY, MD had other recognized risk factors for diabe- 2 6 MAYER B. DAVIDSON, MD RICHARD PRATLEY, MD tes including obesity, a prior history of ges- 3 7 RALPH A. DEFRONZO, MD BERNARD ZINMAN, MD 4 tational diabetes, or a positive family history ROBERT J. HEINE, MD, PHD, FRCP of diabetes. All of these trials demonstrated reductions in the development of diabetes of 25–60% over the period of follow-up. ype 2 diabetes is now epidemic. In the glucose tolerance (IGT), to diabetes may The largest reductions (ϳ60%) were ac- U.S., there has been a 61% increase in take many years; however, current esti- complished with lifestyle interventions T incidence between 1990 and 2001 mates indicate that most individuals (per- aimed at weight loss and increasing physical (1). There are currently 1.5 million new haps up to 70%) with these pre-diabetic activity and with thiazolidinediones cases per year, and the prevalence in 2005 states eventually develop diabetes (4–10). (4,5,24,25,27). Lesser degrees of reduction was almost 21 million (2). The epidemic has During the pre-diabetic state, the risk of a (25–30%) have been achieved with other affected developed and developing coun- CVD event is modestly increased (11–22). drugs (5,23,24,28). tries alike, and the worldwide prevalence of With the development of diabetes, how- The availability of interventions that diabetes is projected to increase dramati- ever, there is a large increase in risk for have been shown to decrease the develop- cally by 2025 (3).
    [Show full text]
  • Gestational Diabetes
    GESTATIONAL DIABETES DEFINITION: A carbohydrate intolerance that is initially recognized during pregnancy. SCREENING: All pregnant women should be screened with a GLUCOSE CHALLENGE TEST (GCT) at 24-28 weeks gestation (if prenatal care begins after 28 weeks, screen at first visit). Screen with GCT at first prenatal visit if any of the following risk factors are present... Previous history of gestational diabetes Glucosuria of > 3% on a random urine specimen On maintenance oral steroids Family history of diabetes Previous macrosomic baby (> 4000 g) Body Mass Index (BMI) >29 If initial screen is negative, re-screen with GCT at 24-28 weeks If initial screen positive, do GLUCOSE TOLERANCE TEST (GTT) o if early GTT negative, repeat only GTT/HgbA1c at 24-28 weeks Glucose Challenge Test (GCT): Patient is given a 50 g oral glucose load (Glucola) without regard to the time of day or time of most recent meal. A venous blood draw is performed one hour later to determine the blood glucose level. Normal GCT < 130 mg/dl Abnormal GCT > 130 mg/dl An abnormal GCT >130 and<200 should be followed by a Glucose Tolerance Test (GTT) within one week. If GCT > 200 mg/ml, return to clinic in AM for fasting blood glucose (FBG). o If FBG >126: patient has diabetes, transfer care to HCMC high risk OB. o If FBG <126: perform GTT and draw Hgb A1C. Glucose Tolerance Test (GTT): Patient fasts starting at midnight. The next morning a fasting glucose level is drawn and then the patient is given a 100 g oral glucose load at the lab.
    [Show full text]
  • Basal Glucose Can Be Controlled, but the Prandial Problem Persistsdit's
    Diabetes Care Volume 40, March 2017 291 Basal Glucose Can Be Controlled, Matthew C. Riddle but the Prandial Problem PersistsdIt’stheNextTarget! PERSPECTIVES IN CARE Diabetes Care 2017;40:291–300 | DOI: 10.2337/dc16-2380 Both basal and postprandial elevations contribute to the hyperglycemic exposure of diabetes, but current therapies are mainly effective in controlling the basal compo- nent. Inability to control postprandial hyperglycemia limits success in maintaining overall glycemic control beyond the first 5 to 10 years after diagnosis, and it is also related to the weight gain that is common during insulin therapy. The “prandial problem”dcomprising abnormalities of glucose and other metabolites, weight gain, and risk of hypoglycemiaddeserves more attention. Several approaches to prandial abnormalities have recently been studied, but the patient populations for which they are best suited and the best ways of using them remain incompletely defined. Encouragingly, several proof-of-concept studies suggest that short-acting glucagon- like peptide 1 agonists or the amylin agonist pramlintide can be very effective in controlling postprandial hyperglycemia in type 2 diabetes in specific settings. This article reviews these topics and proposes that a greater proportion of available resources be directed to basic and clinical research on the prandial problem. Widespread self-testing of blood glucose and, more recently, continuous glucose mon- itoring (CGM) have drawn attention to the daily patterns of blood glucose in both type 1 and type 2 diabetes. Seeing these patterns has allowed separate consideration of fasting (basal) hyperglycemia and after-meal (postprandial) increments of glucose above basal levels. In entirely healthy individuals, fasting plasma glucose is rarely .100 mg/dL (5.5 mmol/L).
    [Show full text]
  • Oral Glucose Tolerance and Mixed Meal Tolerance Tests
    FACT SHEET Oral Glucose Tolerance and Mixed Meal Tolerance Tests General Uses and Considerations The oral glucose tolerance test (OGTT) and mixed meal tolerance test (MMT) are widely used in clinical metabolic research and diabetes drug development. The OGTT and MMTT provide an integrated assessment to the β-cell response to an intestinally-delivered insulin secretory stimulus that includes activation of the incretin axis. The major incretin hormones are glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic peptide (GIP) secreted, respectively, by the L and K cells of the intestine. The incretin effect comprises enhancement of glucose-stimulated insulin secretion from islet β-cells in concert with reduced glucagon release from α-cells. When assessing the response to therapeutic agents whose primary mode of action is via the incretin axis, e.g. dipeptidyl peptidase (DDP)-4 inhibitors, the response of GLP-1 and GIP can be quantified with respect to stimulation of insulin secretion and suppression of glucagon secretion. Oral glucose tolerance test - The 75 g oral glucose tolerance test is the reference method for diagnosing defined categories of glucose intolerance and type 2 diabetes. Mixed meal tolerance test – This provides a more comprehensive physiological stimulus to insulin secretion since β-cells are responsive to certain amino acids and fatty acids in addition to glucose. Subjects and Preparation OGTTs and MMTTs are performed in the morning following an overnight fast of >8 hours. Limitations are placed on strenuous exercise, alcohol, caffeine and tobacco use, all of which may influence insulin sensitivity. Overnight admission to the clinical research facility prior to the clamp procedure helps ensure compliance with these restrictions.
    [Show full text]
  • Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus
    U.S. Preventive Services Task Force Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Recommendation Statement ▲ See related article on Summary of Recommendation and Approximately 15% to 30% of these persons page 103. Evidence will develop type 2 diabetes within 5 years if As published by the U.S. The USPSTF recommends screening for they do not implement lifestyle changes to Preventive Services Task abnormal blood glucose as part of cardio- improve their health.1 Force. vascular risk assessment in adults aged 40 Modifiable risk factors for abnormal glu- This summary is one in a to 70 years who are overweight or obese. cose metabolism (manifested as either dia- series excerpted from the Recommendation State- Clinicians should offer or refer patients with betes or abnormal glucose levels below the ments released by the abnormal blood glucose to intensive behav- threshold for diabetes) include overweight USPSTF. These statements ioral counseling interventions to promote a and obesity or a high percentage of abdomi- address preventive health healthful diet and physical activity (Table 1). nal fat, physical inactivity, and smoking. services for use in primary care clinical settings, B recommendation. Abnormal glucose metabolism is also fre- including screening tests, quently associated with other cardiovascu- counseling, and preventive Rationale lar risk factors, such as hyperlipidemia and medications. IMPORTANCE hypertension. The complete version of Cardiovascular disease (CVD) is the lead- Given the increasing prevalence of abnor- this statement, includ- ing cause of death in the United States, and mal glucose metabolism in the U.S. popula- ing supporting scientific evidence, evidence tables, nearly one-quarter of deaths caused by CVD tion, the USPSTF sought to examine the grading system, members are considered to be preventable.
    [Show full text]
  • Diabetes Mellitus: Fundamentals – a Review and Current Update
    Diabetes Mellitus: Fundamentals – A Review and Current Update Authored by: Virginia G. Miller, PhD, RN, CS, FNP Contact Hours: Valid for 5.0 (ANCC) and 6.0 (ABN) contact hours valid July 21, 2016 through July 21, 2018 Target Audience: Registered Nurses and Licensed Practical Nurses Purpose/Goal: The purpose of this activity is to provide a basic comprehensive review of Diabetes Mellitus Objectives: At the conclusion of this activity the learner should be able to: 1. Explain normal physiology and pathophysiology of Diabetes Mellitus. 2. List 4 cornerstones of Diabetes Mellitus and its effect on blood glucose. Fees: ASNA Member - $40.00 Non-Member - $60.00 Instructions for Credit: Participants should read the purpose/goal and objectives and then study the activity on-line or printed out. Read, complete, and submit answers to the post-test at the end of the activity. Participants must achieve at least 80% on the post-test, complete the evaluation and submit the appropriate fee to receive continuing education credit. Print out the Post-test and evaluation and return the completed sheets to the Alabama State Nurses Association (ASNA) to receive a Certificate of Completion. The Post- test and evaluation sheet may be mailed or faxed to ASNA. Disclosures: The author and Planning Committee have declared no conflict of interest. Certificates: Certificates of Completion will be emailed/mailed within 2 weeks – Hours will be reported to the ABN within 2 weeks of certificate. Accreditation: Alabama Board of Nursing Provider Number ABNP0002 (valid through April 6, 2021). Alabama State Nurses Association 360 N. Hull St.
    [Show full text]